The German National Pandemic Cohort Network (NAPKON): rationale, study design and baseline characteristics

Author:

Schons MaximilianORCID,Pilgram LisaORCID,Reese Jens-PeterORCID,Stecher MelanieORCID,Anton GabrieleORCID,Appel Katharina S.ORCID,Bahmer ThomasORCID,Bartschke AlexanderORCID,Bellinghausen CarlaORCID,Bernemann Inga,Brechtel MarkusORCID,Brinkmann FolkeORCID,Brünn Clara,Dhillon Christine,Fiessler Cornelia,Geisler RamsiaORCID,Hamelmann EckardORCID,Hansch Stefan,Hanses FrankORCID,Hanß Sabine,Herold SusanneORCID,Heyder Ralf,Hofmann Anna-LenaORCID,Hopff Sina MarieORCID,Horn AnnaORCID,Jakob CarolinORCID,Jiru-Hillmann SteffiORCID,Keil ThomasORCID,Khodamoradi YaschaORCID,Kohls MirjamORCID,Kraus Monika,Krefting DagmarORCID,Kunze Sonja,Kurth FlorianORCID,Lieb WolfgangORCID,Lippert Lena JohannaORCID,Lorbeer Roberto,Lorenz-Depiereux Bettina,Maetzler Corina,Miljukov OlgaORCID,Nauck MatthiasORCID,Pape DanielORCID,Püntmann ValentinaORCID,Reinke Lennart,Römmele Christoph,Rudolph StefanieORCID,Sass JulianORCID,Schäfer ChristianORCID,Schaller JensORCID,Schattschneider Mario,Scheer ChristianORCID,Scherer MargareteORCID,Schmidt SeinORCID,Schmidt JuliaORCID,Seibel Kristina,Stahl Dana,Steinbeis FridolinORCID,Störk StefanORCID,Tauchert MaikeORCID,Tebbe Johannes JosefORCID,Thibeault CharlotteORCID,Toepfner NicoleORCID,Ungethüm Kathrin,Vadasz IstvanORCID,Valentin Heike,Wiedmann SilkeORCID,Zoller ThomasORCID,Nagel EikeORCID,Krawczak MichaelORCID,von Kalle ChristofORCID,Illig ThomasORCID,Schreiber Stefan,Witzenrath Martin,Heuschmann PeterORCID,Vehreschild Jörg Janne,

Abstract

AbstractThe German government initiated the Network University Medicine (NUM) in early 2020 to improve national research activities on the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) pandemic. To this end, 36 German Academic Medical Centers started to collaborate on 13 projects, with the largest being the National Pandemic Cohort Network (NAPKON). The NAPKON’s goal is creating the most comprehensive Coronavirus Disease 2019 (COVID-19) cohort in Germany. Within NAPKON, adult and pediatric patients are observed in three complementary cohort platforms (Cross-Sectoral, High-Resolution and Population-Based) from the initial infection until up to three years of follow-up. Study procedures comprise comprehensive clinical and imaging diagnostics, quality-of-life assessment, patient-reported outcomes and biosampling. The three cohort platforms build on four infrastructure core units (Interaction, Biosampling, Epidemiology, and Integration) and collaborations with NUM projects. Key components of the data capture, regulatory, and data privacy are based on the German Centre for Cardiovascular Research. By April 01, 2022, 34 university and 40 non-university hospitals have enrolled 5298 patients with local data quality reviews performed on 4727 (89%). 47% were female, the median age was 52 (IQR 36–62-) and 50 pediatric cases were included. 44% of patients were hospitalized, 15% admitted to an intensive care unit, and 12% of patients deceased while enrolled. 8845 visits with biosampling in 4349 patients were conducted by April 03, 2022. In this overview article, we summarize NAPKON’s design, relevant milestones including first study population characteristics, and outline the potential of NAPKON for German and international research activities.Trial registrationhttps://clinicaltrials.gov/ct2/show/NCT04768998.https://clinicaltrials.gov/ct2/show/NCT04747366.https://clinicaltrials.gov/ct2/show/NCT04679584

Funder

Bundesministerium für Bildung und Forschung

Bayerisches Staatsministerium für Wissenschaft, Forschung und Kunst

Deutsches Zentrum für Infektionsforschung

Deutsche Forschungsgemeinschaft

Bundesland Schleswig Holstein

Universitätsklinikum Köln

Publisher

Springer Science and Business Media LLC

Subject

Epidemiology

Reference59 articles.

1. Bchetnia M, Girard C, Duchaine C, Laprise C. The outbreak of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): a review of the current global status. J Infect Public Health. 2020;13:1601–10.

2. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet (Elsevier). 2020;395:497–506.

3. World Health Organization. Timeline: WHO’s COVID-19 response [Internet]. 2021 [cited 2021 Jul 18]. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/interactive-timeline

4. Elisabeth E. Cameron, Jennifer B. Nuzzo, Jessica A. Bell, et al. Global Health Security Index 2019 [Internet]. 2019. Available from: https://www.ghsindex.org/report-model/

5. WHO. WHO Coronavirus (COVID-19) Dashboard April 01 2022 [Internet]. 2022 [cited 2022 Apr 20]. Available from: https://web.archive.org/web/20220401050337/https://covid19.who.int/

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3